Bromide

Bromide

SCHEMBL18547351

Br.BrCc1ccncc1CBr

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 1/20 0.31
SLC6A4 known ✓ P31645 1/20 0.31
SIGMAR1 known ✓ Q99720 1/20 0.30
AOC1 P19801 9/20 0.41
AOC3 Q16853 9/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
CYP2E1 P05181 2/20 0.32
CYP2C8 P10632 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2A6 P11509 2/20 0.32
CYP2B6 P20813 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2C9 P11712 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8002207 0.97 AOC1 (0.43) AOC1AOC3LOXL2CYP2E1CYP2C8
SCHEMBL8011489 0.84 AOC1 (0.38) AOC1AOC3LOXL2CYP2E1CYP2C8
SCHEMBL844771 0.84 CYP2E1 (0.43) AOC1AOC3LOXL2CYP2E1CYP2C8
SCHEMBL21352027 0.84 AOC1 (0.38) AOC1AOC3LOXL2CYP2A6GAA
SCHEMBL8013767 0.84 AOC1 (0.38) AOC1AOC3LOXL2CYP2E1CYP2C8
Bromide SCHEMBL23161956 0.79 LOXL2 (0.61) AOC1AOC3LOXL2
Bromide SCHEMBL29433932 0.79 AOC1 (0.38) AOC1AOC3LOXL2CYP2E1CYP2C8
Bromide SCHEMBL5042605 0.79 AOC1 (0.38) AOC1AOC3LOXL2
Bromide SCHEMBL844992 0.79 GAA (0.45) AOC1AOC3LOXL2SLC6A2SLC6A4
SCHEMBL2593605 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136326-B2 Pyrrolopyrimidine derivatives as TAM inhibitors INCYTE CORPORATION (US) 2021-10-05 US disclosed
US-20200181151-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS INCYTE CORPORATION 2020-06-11 US disclosed
US-20190031663-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS INCYTE CORPORATION 2019-01-31 US disclosed
US-10053465-B2 Pyrrolopyrimidine derivatives as TAM inhibitors INCYTE CORPORATION (US) 2018-08-21 US disclosed
WO-2017035366-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS INCYTE CORPORATION (US) 2017-03-02 WO disclosed
US-20170057965-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS INCYTE CORPORATION 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136326-B2 Pyrrolopyrimidine derivatives as TAM inhibitors FLT3, MERTK, MIF SLC6A2 4229/4885SLC6A4 4121/4885SIGMAR1 3403/4885
US-20190031663-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS FLT3, MERTK, MIF SLC6A2 4229/4885SLC6A4 4121/4885SIGMAR1 3403/4885
US-10053465-B2 Pyrrolopyrimidine derivatives as TAM inhibitors FLT3, MERTK, MIF SLC6A2 4229/4885SLC6A4 4121/4885SIGMAR1 3403/4885
US-20200181151-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS FLT3, MERTK, MIF SLC6A2 4229/4885SLC6A4 4121/4885SIGMAR1 3403/4885
US-20170057965-A1 PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS FLT3, MERTK, MIF SLC6A2 4229/4885SLC6A4 4121/4885SIGMAR1 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.